[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:diffuse-large-b-cell-lymphoma:ms4a1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Diffuse Large B-Cell Lymphoma","MS4A1 Gene",18,[8,16,23,29,36,42,48,54,60,66,73,79,85,91,97,103,110,117],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06091865","A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma",[12],"Phase 3","RECRUITING","2026-08-26T02:15:41.377360Z","2026-05-29T15:36:40.167745Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06594939","Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma",[20],"Phase 2","2026-08-26T02:18:13.438956Z","2026-05-05T02:43:29.130167Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06458439","Epcoritamab-CAR T Cells for Large B-cell Lymphomas",[20],"2026-08-26T02:17:54.420226Z","2026-05-05T02:43:28.016787Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT07283679","Phase I\u002FII Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",[33],"Phase 1\u002FPhase 2","2026-08-26T02:18:03.638950Z","2026-05-05T02:43:27.977643Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06905509","Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",[20],"2026-08-26T02:15:13.282904Z","2026-05-05T02:43:27.809747Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07365306","Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma",[20],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:27.484467Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05615636","A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL",[20],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:27.476441Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06788964","Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)",[20],"2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.700465Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT07188558","A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",[12],"2026-08-26T02:18:37.277498Z","2026-05-05T02:43:29.052132Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":71,"content_modified":72},"NCT06209619","CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma",[70],"Phase 1","2026-08-26T02:15:10.362237Z","2026-05-05T02:43:28.853554Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05826535","Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma",[33],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.542914Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT02393157","Obinutuzumab and ICE Chemotherapy in Refractory\u002FRecurrent CD20+ Mature NHL",[20],"2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.289405Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT04231877","Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",[70],"2026-08-03T01:58:01.892442Z","2026-05-05T02:43:28.077600Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05990465","LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",[70],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:27.263994Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06693830","ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL",[],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:29.733681Z",{"nct_id":104,"title":105,"phases":106,"status":107,"updated_at":108,"content_modified":109},"NCT07588698","Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma",[20],"NOT_YET_RECRUITING","2026-08-26T02:16:49.565137Z","2026-05-29T15:36:40.200627Z",{"nct_id":111,"title":112,"phases":113,"status":114,"updated_at":115,"content_modified":116},"NCT05421663","A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma",[33],"ACTIVE_NOT_RECRUITING","2026-08-03T03:30:50.548292Z","2026-05-05T02:43:29.152099Z",{"nct_id":118,"title":119,"phases":120,"status":114,"updated_at":121,"content_modified":122},"NCT05412290","Mosunetuzumab Consolidation Therapy After autoSCT in r\u002Fr Aggressive B Cell Lymphoma",[70],"2026-08-03T03:30:23.638222Z","2026-05-05T02:43:28.878051Z"]